Neurogene Inc. (NGNE) Free cash flow 2016–2025
Neurogene Inc. (NGNE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$78.4MFY2025 · since FY2016: -$30.9M → -$78.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$78.4M | -9.7% |
| FY2024 | -$71.4M | -38.0% |
| FY2023 | -$51.7M | +6.0% |
| FY2022 | -$55.1M | -8.3% |
| FY2021 | -$50.8M | -89.7% |
| FY2020 | -$26.8M | -64.7% |
| FY2019 | -$16.3M | +48.5% |
| FY2018 | -$31.6M | +30.0% |
| FY2017 | -$45.2M | -46.1% |
| FY2016 | -$30.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice